Organ-preserving surgical treatment of a patient with synchronous bilateral morphologically different renal cell carcinoma, inferior vena cava tumor thrombus and pyeloureteral segment stone: clinical case

Cover Page

Cite item

Full Text

Abstract

Kidney cancer is the 3rd most common disease in oncological urology. In 4–10 % cases, tumor thrombus of the inferior vena cava is diagnosed. In literature, single-digit number of cases of organ-preserving surgical treatment of patients with kidney cancer complicated by tumor thrombus is described. The article presents a rare clinical case of synchronous bilateral morphologically different kidney cancer with tumor thrombus in the left renal vein, perirenal segment of the inferior vena cava, pyeloureteral segment stone in the right ureter.

About the authors

K. A. Turupaev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia;
Russian University of Medicine, Ministry of Health of Russia

Author for correspondence.
Email: Kir-turupaev@yandex.ru
ORCID iD: 0000-0001-8887-5108

Kirill A. Turupaev 

23 Kashirskoe Shosse, Moscow 115522,

Build. 1, 20 Delegatskaya St., Moscow 127473

Russian Federation

A. V. Klimov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0003-0727-2976

23 Kashirskoe Shosse, Moscow 115522

Russian Federation

O. A. Khalmurzaev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0001-7500-1815

23 Kashirskoe Shosse, Moscow 115522

Russian Federation

G. A. Arakelyan

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0003-3528-1466

23 Kashirskoe Shosse, Moscow 115522

Russian Federation

D. D. Ladyko

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: DDLadyko@yandex.ru
ORCID iD: 0009-0009-5878-6951

23 Kashirskoe Shosse, Moscow 115522

Russian Federation

S. D. Bezhanova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0001-7336-9210

23 Kashirskoe Shosse, Moscow 115522

Russian Federation

V. O. Vorob’eva

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-6704-3676

23 Kashirskoe Shosse, Moscow 115522

Russian Federation

A. V. Smirnova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0003-3240-4141

23 Kashirskoe Shosse, Moscow 115522

Russian Federation

V. B. Matveev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0001-7748-9527

23 Kashirskoe Shosse, Moscow 115522

Russian Federation

References

  1. Globocan (IARC) 2020. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/29-Kidney-fact-sheet.pdf.
  2. State of oncological care in Russia in 2021. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022. 239 p. (In Russ.).
  3. Zhang C., Li X., Hao H. et al. The correlation between size of renal cell carcinoma and its histopathological characteristics: a single center study of 1867 renal cell carcinoma cases. BJU Int 2012; 110(11 Pt B):E481–5. doi: 10.1111/j.1464-410X.2012.11173.x
  4. Van Poppel H., Da Pozzo L., Albrecht W. et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011;59(4):543–52. doi: 10.1016/j.eururo.2010.12.013
  5. Scosyrev E., Messing E.M., Sylvester R. et al. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur Urol 2014;65(2):372–7. doi: 10.1016/j.eururo.2013.06.044
  6. Fergany A.F., Hafez K.S., Novick A.C. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol 2000;163(2):442–5.
  7. Patel S.H., Uzzo R.G., Larcher A. et al. Oncologic and functional outcomes of radical and partial nephrectomy in pt3a pathologically upstaged renal cell carcinoma: a multi-institutional analysis. Clin Ge-nitourin Cancer 2020;18(6):e723–9. doi: 10.1016/j.clgc.2020.05.002
  8. Kolla S.B., Ercole C., Spiess P.E. et al. Nephron-sparing surgery for pathological stage T3b renal cell carcinoma confined to the renal vein. BJU Int 2010;106(10):1494–8. doi: 10.1111/j.1464-410X.2010.09293.x
  9. Yim K., Aron M., Rha K.H. et al. Outcomes of robot-assisted partial nephrectomy for clinical T3a renal masses: a multicenter analysis. Eur Urol Focus 2021;7(5):1107–14. doi: 10.1016/j.euf.2020.10.011
  10. Woldu S.L., Barlow L.J., Patel T. et al. Single institutional experience with nephron-sparing surgery for pathologic stage T3bNxM0 renal cell carcinoma confined to the renal vein. Urology 2010;76(3):639–42. doi: 10.1016/j.urology.2009.10.073
  11. Marra G., Gontero P., Brattoli M. et al. Is imperative partial nephrectomy feasible for kidney cancer with venous thrombus involvement? Outcomes of 42 cases and matched pair analysis with a large radical nephrectomy cohort. Urol Oncol 2018;36(7):339.e1–8. doi: 10.1016/j.urolonc.2018.04.007
  12. Morgan T.N., Dai J.C., Kusin S. et al. Clinical outcomes of robotic assisted partial nephrectomy for pathologic T3a renal masses with venous tumor thrombus. Urology 2022;159:120–6. doi: 10.1016/j.urology.2021.06.054
  13. Zisman A., Pantuck A.J., Wieder J. et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002;20(23):4559–66. doi: 10.1200/JCO.2002.05.111
  14. Leibovich B.C., Blute M.L., Cheville J.C. et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97(7):1663–71. doi: 10.1002/cncr.11234
  15. Eisen T., Frangou E., Oza B. et al. Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized phase III intergroup trial. J Clin Oncol 2020;38:4064–75. doi: 10.1200/JCO.20.01800
  16. Gross-Goupil M., Kwon T., Eto M. et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol 2018;29(12):2371–8. doi: 10.1093/annonc/mdy454
  17. Haas N.B., Manola J., Uzzo R.G. et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016;387(10032):2008–16. doi: 10.1016/S0140-6736(16)00559-6
  18. Motzer R.J., Haas N.B., Donskov F. et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 2017;35(35):3916–23. doi: 10.1200/JCO.2017.73.5324
  19. Staehler M., Motzer R.J., George D.J. et al. Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. Ann Oncol 2018;29(10):2098–104. doi: 10.1093/annonc/mdy329
  20. Powles T., Tomczak P., Park S.H. et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022;23(9):1133–44. doi: 10.1016/S1470-2045(22)00487-9

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.